Millennium Management LLC reduced its position in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 32.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 209,611 shares of the company's stock after selling 100,366 shares during the quarter. Millennium Management LLC owned approximately 0.12% of HUTCHMED worth $3,020,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also bought and sold shares of the company. XY Capital Ltd purchased a new position in shares of HUTCHMED in the fourth quarter valued at $673,000. ABC Arbitrage SA bought a new stake in HUTCHMED during the fourth quarter valued at $500,000. Jane Street Group LLC boosted its stake in HUTCHMED by 54.7% during the fourth quarter. Jane Street Group LLC now owns 97,470 shares of the company's stock valued at $1,405,000 after buying an additional 34,473 shares during the period. Renaissance Technologies LLC boosted its stake in HUTCHMED by 18.4% during the fourth quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock valued at $2,717,000 after buying an additional 29,239 shares during the period. Finally, Marshall Wace LLP bought a new stake in HUTCHMED during the fourth quarter valued at $261,000. 8.82% of the stock is owned by hedge funds and other institutional investors.
HUTCHMED Price Performance
Shares of NASDAQ HCM traded up $0.60 during midday trading on Wednesday, reaching $15.30. The company had a trading volume of 105,379 shares, compared to its average volume of 100,670. HUTCHMED has a one year low of $11.51 and a one year high of $21.50. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The firm's fifty day moving average price is $14.06 and its 200-day moving average price is $14.82.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the company. Wall Street Zen lowered HUTCHMED from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. HSBC lowered HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th.
View Our Latest Research Report on HCM
HUTCHMED Company Profile
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
